Login to Your Account



Clinic Roundup


Thursday, October 11, 2012
• Immunovaccine Inc., of Halifax, Nova Scotia, reported interim results from its Phase I trial of DPX-Survivac, an ovarian cancer vaccine, showing that, to date, all nine patients receiving the vaccine in combination with low-dose oral cyclophosphamide produced a targeted immune response following only one or two vaccine administrations.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription